Moreover, it is important to mention that the role of PD-1/PD-L1 inhibitors in oncogene-addicted NSCLC remains uncertain, as tyrosine kinase inhibitors (TKIs) are currently the standard of care for patients with EGFR or ALK alterations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.